Brief: Urogen Submits Application Supporting Planned Phase 1 Study Of UGN-301 Intravesical Solution In Recurrent Non-Muscle Invasive Bladder Cancer
01/03/2022 16:36
March 1 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN SUBMITS INVESTIGATIONAL NEW DRUG APPLICATION
SUPPORTING
PLANNED PHASE 1 CLINICAL STUDY OF UGN-301 (ZALIFRELIMAB)
INTRAVESICAL SOLUTION IN RECURRENT NON-MUSCLE INVASIVE BLADDER
CANCER
* UROGEN PHARMA LTD - STUDY IS EXPECTED TO BEGIN IN Q2 OF
2022
Source text for Eikon: ID:nBwQr4NKa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors